CH619365A5 - - Google Patents
Download PDFInfo
- Publication number
- CH619365A5 CH619365A5 CH1062276A CH1062276A CH619365A5 CH 619365 A5 CH619365 A5 CH 619365A5 CH 1062276 A CH1062276 A CH 1062276A CH 1062276 A CH1062276 A CH 1062276A CH 619365 A5 CH619365 A5 CH 619365A5
- Authority
- CH
- Switzerland
- Prior art keywords
- uric acid
- adenine
- guanine
- gout
- acid
- Prior art date
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 29
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 29
- 229940116269 uric acid Drugs 0.000 claims description 29
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 16
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 8
- 229930024421 Adenine Natural products 0.000 claims description 8
- 229960000643 adenine Drugs 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims 1
- 201000005569 Gout Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 201000001431 Hyperuricemia Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 230000029142 excretion Effects 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000003748 differential diagnosis Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012050 conventional carrier Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000004144 purine metabolism Effects 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 150000001887 cortisones Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000004147 pyrimidine metabolism Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
- Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
- Y10T436/148888—Uric acid
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19752537488 DE2537488C2 (de) | 1975-08-22 | Mittel zur Durchführung eines Harnsäure-Belastungstests |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH619365A5 true CH619365A5 (enExample) | 1980-09-30 |
Family
ID=5954641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1062276A CH619365A5 (enExample) | 1975-08-22 | 1976-08-20 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4101648A (enExample) |
| AT (1) | AT347602B (enExample) |
| CH (1) | CH619365A5 (enExample) |
| FR (1) | FR2321292A1 (enExample) |
| GB (1) | GB1561358A (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2263315C2 (ru) * | 2002-03-19 | 2005-10-27 | Нижегородский научно-исследовательский институт детской гастроэнтерологии | Способ дифференциальной диагностики обострения и ремиссии гастродуоденальных заболеваний у детей |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE757653A (fr) * | 1969-10-21 | 1971-04-16 | Ugine Kuhlmann | Nouveaux medicaments derives d'acides nucleiques et procedes pour leur preparation |
-
1976
- 1976-08-18 AT AT613776A patent/AT347602B/de not_active IP Right Cessation
- 1976-08-20 CH CH1062276A patent/CH619365A5/de not_active IP Right Cessation
- 1976-08-23 GB GB35054/76A patent/GB1561358A/en not_active Expired
- 1976-08-23 FR FR7625461A patent/FR2321292A1/fr active Granted
- 1976-08-23 US US05/716,549 patent/US4101648A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| FR2321292A1 (fr) | 1977-03-18 |
| GB1561358A (en) | 1980-02-20 |
| ATA613776A (de) | 1978-05-15 |
| FR2321292B1 (enExample) | 1978-11-17 |
| DE2537488B1 (de) | 1976-03-25 |
| AT347602B (de) | 1979-01-10 |
| US4101648A (en) | 1978-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69121561T2 (de) | Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht | |
| DE602004006895T2 (de) | Verfahren zur behandlung von multipler sklerose | |
| Fischer et al. | The tissue distribution and excretion of radioactive digitoxin: studies on normal rats and cats, and rats with dietary-induced myocardial lesions | |
| DE2701462A1 (de) | Biologisches konkurrenzbindungs-nachweisverfahren zur bestimmung des serumschilddruesenhormons | |
| DE60022185T2 (de) | Verfahren zum screening von arzneizubereitungen | |
| Levine et al. | The physiological disposition of oxyphenonium bromide (antrenyl) and related compounds | |
| DE2616491C2 (de) | Arzneimittel mit hemmender Wirkung auf die Agglutination der Blutplättchen | |
| DE3212736A1 (de) | Verwendung von dihydropyridinen in arzneimitteln mit salidiuretischer wirkung | |
| EP0398165B1 (de) | Kombinationspräparate enthaltend Rifampicin und Thioacetazon sowie gegebenenfalls Isonicotinsäurehydrazid oder Ethambutol als aktive Wirkstoffe | |
| DE2840760A1 (de) | Verfahren und reagens zum nachweis von kanzerogenen und antikanzerogenen substanzen | |
| DE69520591T2 (de) | Bestimmung von steroid sulfatase | |
| DE2902071A1 (de) | Verfahren und reagens zur bestimmung der konzentration von benzodiazepinen in einer koerperfluessigkeit | |
| DE2537488C2 (de) | Mittel zur Durchführung eines Harnsäure-Belastungstests | |
| CH619365A5 (enExample) | ||
| DE69515321T2 (de) | Brefeldin a und analoge zur verbesserung synaptischer übertragungen | |
| WO2002027325A1 (de) | Verfahren zur diagnose der laktose-intoleranz und diagnosekit zur durchführung des verfahrens | |
| Herman et al. | Fatal thyrotoxic crisis | |
| Haley et al. | Pharmacology and toxicology of potassium perrhenate and rhenium trichloride | |
| DE2147066C3 (de) | Verfahren und Schnelltest-Tablette zur orientierenden selektiven Schnellbestimmung von Calcium Im Harn | |
| Rosen et al. | Absorption and excretion of radioactively tagged dextroamphetamine sulfate from a sustained-release preparation | |
| DE2011499A1 (de) | Arzneimittel aus Germaniumsäure und Cystein und Verfahren zu seiner Herstellung | |
| DE69636412T2 (de) | Ginkgolide zur hemmung der membranexpression | |
| Jones et al. | Effects of denervation and reinnervation on the responses of kitten muscles to acetylcholine and suxamethonium | |
| CHOW et al. | Factors affecting the absorption of vitamin B12 | |
| DE3874978T2 (de) | Ponalrestat enthaltendes hyperurikaemie-mittel. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |